From Wikipedia, the free encyclopedia
Vasodilatory shock
Other namesRefractory vasodilatory shock, refractory shock, irreversible shock, vasogenic shock, or vasoplegic shock.
Specialty Emergency medicine
Complications Multiple organ dysfunction
PreventionEarly recognition and rapid treatment initiation for any types of shock.
PrognosisHigher than 50% mortality rate within a month [1][ dubious ]

Vasodilatory shock, vasogenic shock, or vasoplegic shock is a medical emergency belonging to shock along with cardiogenic shock, septic shock, allergen-induced shock and hypovolemic shock. When the blood vessels suddenly relax, it results in vasodilation. In vasodilatory shock, the blood vessels are too relaxed leading to extreme vasodilation and blood pressure drops and blood flow becomes very low. Without enough blood pressure, blood and oxygen will not be pushed to reach the body's organs. If vasodilatory shock lasts more than a few minutes, the lack of oxygen starts to damage the body's organs. [2] Vasodilatory shock like other types of shock should be treated quickly, otherwise it can cause permanent organ damage or death as a result of multiple organ dysfunction. [3] [4] [5] [6]

Treatment typically involves uses of vasopressor, inotropes, fluid boluses, and introduction of resuscitation. [4] In case vasodilatory shock fails to respond to high doses of vasopressors (defined as ≥ 0.5 mg/kg/min norepinephrine-equivalent dose [7]), meaning it's vasopressor-resistant and advances to being called refractory vasodilatory shock or simply refractory shock. [4] [8] Adjunctive therapies include angiotensin II, hydrocortisone, thiamine, catecholamines, ascorbic acid and combinations of thereof. [4] [9] [10]

Signs and symptoms

  • Confusion or lack of alertness
  • Loss of consciousness
  • A sudden and ongoing rapid heartbeat
  • Sweating
  • Pale skin
  • A weak pulse
  • Rapid breathing
  • Decreased or no urine output
  • Cool hands and feet

[3]

Cause

A bacterial infection in the bloodstream, [11] a severe allergic reaction ( anaphylaxis), systemic inflammatory response syndrome, [12] or damage to the nervous system ( brain and nerves) may cause vasodilatory shock. [3] [12] [13] Besides, nearly all kinds of distributive shock such as septic shock, neurogenic shock, anaphylactic shock, drug and toxin-induced shock, endocrine shock can turn out into refractory vasodilatory shock when the original shock becomes more severe. [14] [2] [15] [16] [17] [4]

The most common cause of vasodilatory shock is sepsis. [5] Except sepsis, other causes comprise severe acute pancreatitis, post cardiopulmonary bypass vasoplegia and other triggers for a systemic inflammatory response syndrome. [18] [19] [20] [21] Low serum calcium values might take a role in vasodilatory shock. [17]

Pathophysiology

In the cases of cardiogenic shock resulting from heart failure or acute hemorrhagic shock caused by a large volume of blood loss, the body constricts peripheral vessels to reverse the low arterial pressure that causes inadequate tissue perfusion. [22] With vasodilatory shock, it is difficult for the peripheral vascular smooth muscle to constrict. [22] In refractory vasodilatory shock, peripheral vascular smooth muscle responds poorly to therapy with vasopressor drugs. [22]

Vasopressin deficiency may play an important role in vasodilatory shock. [23] In refractory vasodilatory shock, the patient has both vasopressin secretion deficit and an advanced resistance to vasopressin-induced blood-pressure changes. [23] Some have hypothesized that patients with vasopressin deficiency, including a decrease in baroreceptor stimulation, appear to have impaired autonomic reflexes. [23] Tone may be inhibited by atrial stretch receptors and vasopressin release may be inhibited by nitric oxide or high circulating levels of norepinephrine. [23]

Vasodilatory shock is often involved with the dysfunction of physiologic compensatory mechanisms such as the sympathetic nervous system, vasopressin arginine system and renin-angiotensin aldosterone system. [24]

[5] [6]

Diagnosis

The definition of refractory shock or vasodilatory shock varies. In 2018, the American College of Chest Physician stated that it is presents if there is an inadequate response to high-dose vasopressor therapy defined as ≥ 0.5 mg/kg/min norepinephrine-equivalent dose. [4]

Drug Dose Norepiniphrine equivalent
Epinephrine 0.1 μg/Kg/min 0.1 μg/Kg/min
Dopamine 15 μg/Kg/min 0.1 μg/Kg/min
Norepinephrine 0.1 μg/Kg/min 0.1 μg/Kg/min
Phenylephrine 1 μg/Kg/min 0.1 μg/Kg/min
Vasopressin 0.04 U/Kg/min 0.1 μg/Kg/min

[15] [25] [26] [27]

Management

Reversing the underlying causes of vasodilatory shock, stabilizing hemodynamic, preventing renal, myocardial, and other organs from injuries due to hypoperfusion and hypoxia, and taking necessary measures to safeguard against complications including venous thromboembolism are served as the top priorities during the treatment. [24]

The initial treatment aiming at restoring effective blood pressure in patients that have refractory shock typically starts with introducing norepinephrine and dopamine. [24] Vasopressin comes as the second-line agent. [24]

However, high-dose therapy is linked to excessive coronary, splanchnic vasoconstriction, and hypercoagulation. [6] Excessive vasoconstriction can cause cardiac output reduction or even fatal heart complication particularly in those with weak myocardial function. [6]

[4] [28] [29]

In those whose vasodilatory shock is caused by hypocalcemic cardiomyopathy in the context of dilated cardiomyopathy with documented both reduced heart ejection fraction and contractile performance, [17] the uses of calcium and active vitamin D or recombinant human parathyroid hormone treatment are viable since there were many successful cases reported while given the physiological role of calcium on muscle contraction. [17] [30] [31] [32]

A successful treatment requires leveraging the respective unique contributions of a multi-disciplinary team not only critical care doctors and often, infectious disease specialists but also respiratory therapy, nursing, pharmacy and others in collaboration. [24]

Epidemiology

Observational studies suggest that, about 6% to 7% of critically ill people may end up developing refractory shock. [33] [34]

Prognosis

Early recognition and rapid treatment initiation are crucial to saving life. [24] If vasodilatory shock being left untreated, even brief hypotensive periods can result in myocardial and renal injury. [21] [35] It can also increased mortality in the critically ill. [21] Refractory shock has an all-cause mortality rate greater than 50% within a month [1][ dubious ].

References

  1. ^ a b Auchet, Thomas; Regnier, Marie-Alix; Girerd, Nicolas; Levy, Bruno (2017-04-20). "Outcome of patients with septic shock and high-dose vasopressor therapy". Annals of Intensive Care. 7 (1): 43. doi: 10.1186/s13613-017-0261-x. ISSN  2110-5820. PMC  5397393. PMID  28425079.
  2. ^ a b Vincent, Jean-Louis; De Backer, Daniel (2013-10-31). Finfer, Simon R.; Vincent, Jean-Louis (eds.). "Circulatory Shock". The New England Journal of Medicine. 369 (18): 1726–1734. doi: 10.1056/nejmra1208943. ISSN  0028-4793. PMID  24171518. S2CID  6900105.
  3. ^ a b c "National Heart, Lung, and Blood Institute (NHLBI)". Cardiogenic Shock. Retrieved 2019-02-07. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ a b c d e f g Jentzer, Jacob C.; Vallabhajosyula, Saraschandra; Khanna, Ashish K.; Chawla, Lakhmir S.; Busse, Laurence W.; Kashani, Kianoush B. (2018). "Management of Refractory Vasodilatory Shock". Chest. 154 (2): 416–426. doi: 10.1016/j.chest.2017.12.021. ISSN  0012-3692. PMID  29329694. S2CID  206678750.
  5. ^ a b c Gkisioti, S; Mentzelopoulos, SD (2011). "Vasogenic shock physiology". Open Access Emergency Medicine. 3: 1–6. doi: 10.2147/OAEM.S10388. ISSN  1179-1500. PMC  4753960. PMID  27147845.
  6. ^ a b c d Lambden, Simon; Creagh-Brown, Ben C.; Hunt, Julie; Summers, Charlotte; Forni, Lui G. (2018-07-06). "Definitions and pathophysiology of vasoplegic shock". Critical Care. 22 (1): 174. doi: 10.1186/s13054-018-2102-1. ISSN  1364-8535. PMC  6035427. PMID  29980217.
  7. ^ Bassi, Estevão; Park, Marcelo; Azevedo, Luciano Cesar Pontes (2013). "Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock". Critical Care Research and Practice. 2013: 1–10. doi: 10.1155/2013/654708. ISSN  2090-1305. PMC  3787628. PMID  24151551.
  8. ^ Masarwa, Reem; Paret, Gideon; Perlman, Amichai; Reif, Shimon; Raccah, Bruria Hirsh; Matok, Ilan (2017-01-05). "Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis". Critical Care. 21 (1): 1. doi: 10.1186/s13054-016-1589-6. ISSN  1364-8535. PMC  5217634. PMID  28057037.
  9. ^ Khanna, Ashish; English, Shane W.; Wang, Xueyuan S.; Ham, Kealy; Tumlin, James; Szerlip, Harold; Busse, Laurence W.; Altaweel, Laith; Albertson, Timothy E.; Mackey, Caleb; McCurdy, Michael T.; Boldt, David W.; Chock, Stefan; Young, Paul J.; Krell, Kenneth; Wunderink, Richard G.; Ostermann, Marlies; Murugan, Raghavan; Gong, Michelle N.; Panwar, Rakshit; Hästbacka, Johanna; Favory, Raphael; Venkatesh, Balasubramanian; Thompson, B. Taylor; Bellomo, Rinaldo; Jensen, Jeffrey; Kroll, Stew; Chawla, Lakhmir S.; Tidmarsh, George F.; Deane, Adam M. (2017-08-03). "Angiotensin II for the Treatment of Vasodilatory Shock" (PDF). The New England Journal of Medicine. 377 (5): 419–430. doi: 10.1056/nejmoa1704154. ISSN  0028-4793. PMID  28528561.
  10. ^ Dünser, M.; Wenzel, V.; Mayr, A. J.; Hasibeder, W. R. (2002-08-01). "Arginin-Vasopressin im vasodilatatorischen Schock". Der Anaesthesist (in German). 51 (8): 650–659. doi: 10.1007/s00101-002-0349-y. ISSN  0003-2417. PMID  12391525. S2CID  33545204.
  11. ^ Singer, Mervyn; Deutschman, Clifford S.; Seymour, Christopher Warren; Shankar-Hari, Manu; Annane, Djillali; Bauer, Michael; Bellomo, Rinaldo; Bernard, Gordon R.; Chiche, Jean-Daniel; Coopersmith, Craig M.; Hotchkiss, Richard S.; Levy, Mitchell M.; Marshall, John C.; Martin, Greg S.; Opal, Steven M.; Rubenfeld, Gordon D.; van der Poll, Tom; Vincent, Jean-Louis; Angus, Derek C. (2016-02-23). "The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)". JAMA. 315 (8): 801–10. doi: 10.1001/jama.2016.0287. ISSN  0098-7484. PMC  4968574. PMID  26903338.
  12. ^ a b Williams, Felicia N; Herndon, David N; Hawkins, Hal K; Lee, Jong O; Cox, Robert A; Kulp, Gabriela A; Finnerty, Celeste C; Chinkes, David L; Jeschke, Marc G (2009). "The leading causes of death after burn injury in a single pediatric burn center". Critical Care. 13 (6): R183. doi: 10.1186/cc8170. ISSN  1364-8535. PMC  2811947. PMID  19919684.
  13. ^ Banks, Peter A; Bollen, Thomas L; Dervenis, Christos; Gooszen, Hein G; Johnson, Colin D; Sarr, Michael G; Tsiotos, Gregory G; Vege, Santhi Swaroop (January 2013). "Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus". Gut. 62 (1): 102–111. doi: 10.1136/gutjnl-2012-302779. hdl: 11336/29220. ISSN  0017-5749. PMID  23100216.
  14. ^ "Definition, classification, etiology, and pathophysiology of shock in adults". UpToDate. Retrieved 2019-02-07.
  15. ^ a b De Backer, Daniel; Biston, Patrick; Devriendt, Jacques; Madl, Christian; Chochrad, Didier; Aldecoa, Cesar; Brasseur, Alexandre; Defrance, Pierre; Gottignies, Philippe; Vincent, Jean-Louis (2010-03-04). "Comparison of Dopamine and Norepinephrine in the Treatment of Shock". The New England Journal of Medicine. 362 (9): 779–789. doi: 10.1056/nejmoa0907118. ISSN  0028-4793. PMID  20200382. S2CID  2208904.
  16. ^ Kheng, Cheah P; Rahman, Nik H (2012-07-24). "The use of end-tidal carbon dioxide monitoring in patients with hypotension in the emergency department". International Journal of Emergency Medicine. 5 (1): 31. doi: 10.1186/1865-1380-5-31. ISSN  1865-1380. PMC  3585511. PMID  22828152.
  17. ^ a b c d Minisola, Salvatore; Cipriani, Cristiana; Colangelo, Luciano; Biamonte, Federica; Pepe, Jessica (2019). "Serum Calcium Values and Refractory Vasodilatory Shock". Chest. 155 (1): 242. doi: 10.1016/j.chest.2018.08.1066. ISSN  0012-3692. PMID  30616730.
  18. ^ Sablotzki, Armin; Friedrich, Ivar; Mühling, Jörg; Dehne, Marius G; Spillner, Jan; Silber, Rolf E; Czeslik, Elke (2002). "The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions". Perfusion. 17 (2): 103–109. doi: 10.1177/026765910201700206. ISSN  0267-6591. PMID  11958300. S2CID  208361755.
  19. ^ Hirai, S (2003). "Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass". Annals of Thoracic and Cardiovascular Surgery. 9 (6): 365–70. ISSN  1341-1098. PMID  15003097.
  20. ^ Herget-Rosenthal, S.; Saner, F.; Chawla, L. S. (2008-02-20). "Approach to Hemodynamic Shock and Vasopressors". Clinical Journal of the American Society of Nephrology. 3 (2): 546–553. doi: 10.2215/cjn.01820407. ISSN  1555-9041. PMC  6631076. PMID  18256381.
  21. ^ a b c Vallabhajosyula, S.; Jentzer, J. C.; Khanna, A. K. (2018). "Vasodilatory Shock in the ICU: Perils, Pitfalls and Therapeutic Options". Annual Update in Intensive Care and Emergency Medicine 2018. Cham: Springer International Publishing. pp. 99–111. doi: 10.1007/978-3-319-73670-9_9. ISBN  978-3-319-73669-3. ISSN  2191-5709.
  22. ^ a b c Landry, Donald W.; Oliver, Juan A. (2001-08-23). Epstein, Franklin H. (ed.). "The Pathogenesis of Vasodilatory Shock". New England Journal of Medicine. 345 (8): 588–595. doi: 10.1056/nejmra002709. ISSN  0028-4793. PMID  11529214.
  23. ^ a b c d Silverstein, Deborah C. (2009). "Vasopressin". Small Animal Critical Care Medicine. Elsevier. pp. 759–762. doi: 10.1016/b978-1-4160-2591-7.10177-8. ISBN  978-1-4160-2591-7.
  24. ^ a b c d e f Timothy E. Albertson. "Advances in Vasodilatory Shock: Emerging Data to Address Current Challenges". Medscape Education. Retrieved 2019-02-08.
  25. ^ Annane, Djillali; Vignon, Philippe; Renault, Alain; Bollaert, Pierre-Edouard; Charpentier, Claire; Martin, Claude; Troché, Gilles; Ricard, Jean-Damien; Nitenberg, Gérard; Papazian, Laurent; Azoulay, Elie; Bellissant, Eric (2007). "Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial". The Lancet. 370 (9588): 676–684. doi: 10.1016/s0140-6736(07)61344-0. ISSN  0140-6736. PMID  17720019. S2CID  25225709.
  26. ^ Myburgh, JA; Higgins, A; Jovanovska, A; Lipman, J; Ramakrishnan, N; Santamaria, J (2008). "A comparison of epinephrine and norepinephrine in critically ill patients". Intensive Care Medicine. 34 (12): 2226–34. doi: 10.1007/s00134-008-1219-0. ISSN  0342-4642. PMID  18654759. S2CID  27732980.
  27. ^ Wakefield, Brett J.; Sacha, Gretchen L.; Khanna, Ashish K. (2018). "Vasodilatory shock in the ICU and the role of angiotensin II". Current Opinion in Critical Care. 24 (4): 277–285. doi: 10.1097/mcc.0000000000000517. ISSN  1070-5295. PMID  29877879. S2CID  46959811.
  28. ^ Levy, Bruno; Fritz, Caroline; Tahon, Elsa; Jacquot, Audrey; Auchet, Thomas; Kimmoun, Antoine (2018-02-27). "Vasoplegia treatments: the past, the present, and the future". Critical Care. 22 (1): 52. doi: 10.1186/s13054-018-1967-3. ISSN  1364-8535. PMC  6389278. PMID  29486781.
  29. ^ Bansal, Beena; Bansal, Manish; Bajpai, Pankaj; Garewal, Hardeep Kaur (2014). "Hypocalcemic Cardiomyopathy—Different Mechanisms in Adult and Pediatric Cases". The Journal of Clinical Endocrinology and Metabolism. 99 (8): 2627–2632. doi: 10.1210/jc.2013-3352. ISSN  0021-972X. PMID  24840807.
  30. ^ Ballane, Ghada T; Sfeir, Jad G; Dakik, Habib A; Brown, Edward M; El-Hajj Fuleihan, Ghada (2012). "Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy". European Journal of Endocrinology. 166 (6): 1113–1120. doi: 10.1530/eje-11-1094. ISSN  0804-4643. PMID  22430263.
  31. ^ Pepe, Jessica; Cipriani, Cristiana; Sonato, Chiara; Raimo, Orlando; Biamonte, Federica; Minisola, Salvatore (2017). "Cardiovascular manifestations of primary hyperparathyroidism: a narrative review". European Journal of Endocrinology. 177 (6): R297–R308. doi: 10.1530/eje-17-0485. ISSN  0804-4643. PMID  28864535.
  32. ^ Benbenishty, Julie; Weissman, Charles; Sprung, Charles L.; Brodsky-Israeli, Mali; Weiss, Yoram (2011). "Characteristics of patients receiving vasopressors". Heart & Lung. 40 (3): 247–252. doi: 10.1016/j.hrtlng.2010.04.007. ISSN  0147-9563. PMID  20630594.
  33. ^ Jenkins, CR; Gomersall, CD; Leung, P; Joynt, GM (2009). "Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study". Anaesthesia and Intensive Care. 37 (2): 286–9. doi: 10.1177/0310057X0903700212. ISSN  0310-057X. PMID  19400494.
  34. ^ Maheshwari, Kamal; Nathanson, Brian H.; Munson, Sibyl H.; Khangulov, Victor; Stevens, Mitali; Badani, Hussain; Khanna, Ashish K.; Sessler, Daniel I. (2018). "The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients". Intensive Care Medicine. 44 (6): 857–867. doi: 10.1007/s00134-018-5218-5. ISSN  0342-4642. PMC  6013508. PMID  29872882.